PHOTO
Abu Dhabi: As the UAE government has identified widespread, accurate testing as a proven effective measure to curb the spread of COVID-19, National Reference Laboratory (NRL) is upscaling its operations to increase its capacity for testing from 3,500 to 6,000 per day.
Hasan Jasem Al Nowais, Senior Vice President of Mubadala Healthcare, says: “Our NRL facility was able to help the national effort as it possesses the scalable infrastructure, diagnostic capabilities and professional support that were required to take on this vital role quickly and reliably.”
He added: “All Mubadala Healthcare facilities are joining forces as part of the countrywide effort to tackle COVID-19 and alleviate its impact on the population and economy. We believe it is our duty to do everything we can to help the UAE successfully navigate this challenge.”
NRL is one of only a few laboratories in the country that performs COVID-19 testing in a Biosafety Level-3 (BSL-3) laboratory. Such laboratories conform to the highest level of standards required by the World Health Organization (WHO) for widespread diagnostic testing for COVID-19. In line with WHO and the Centers for Disease Control and Prevention (CDC) recommendations, NRL tests all samples separately, while maintaining a fast turn-around time.
Abdul Hamid Oubeisi, Chief Executive Officer of NRL, explains: “When the situation arose, NRL rapidly implemented a test method validation and developed a comprehensive workflow for onsite COVID-19 testing to perform accurate and rapid polymerase chain reaction (PCR) testing for COVID-19.”
He adds: “NRL’s infrastructure, technology and manpower – which includes 14 pathologists and clinical scientists and more than 200 medical laboratory technologists – allows for the processing of a high number of samples. The laboratory functions 24/7 to accommodate the demand, and due to our robust laboratory network, we could deploy a large number of skilled medical technologists to assure complete coverage at any time for this project.”
NRL Chief Medical Officer, Dr. Basel Altrabulsi, points out that there are different types of testing available for COVID-19, each with its own advantages, and that NRL is capable of taking on whichever measures are deemed most suitable by the UAE government with immediate effect.
Dr. Altrabulsi explains: “The current molecular diagnostic testing relies on a technology called PCR and searches for evidence of the virus’s RNA genome. Viral RNA-based tests are useful in the acute illness setting and for individual patient management, as well as implementing strategies to prevent the spread in healthcare facilities and the community.
“However, we are also evaluating a blood-test technique, called serological (or antibody) testing. This type of blood testing may not be as useful in the setting of acute illness, but instead is very useful in contact tracing and surveillance at a local or national level.”
Dr. Altrabulsi concludes: “In my opinion, both of these type of tests are important tools to control and reveal the full scope of this outbreak. We are in the fortunate position of being able to mobilize whatever testing protocols are required.”
CEO Oubeisi adds: “NRL is also collaborating with several academic institutions in the UAE to fast-track research projects related to COVID-19. Since research and findings on this topic are evolving daily, NRL is doing everything it can to positively contribute and stay at the forefront of this research so that it will be able to play its part in supporting the UAE government.”
-Ends-
About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for its shareholder, the Government of Abu Dhabi.
Mubadala’s US $229 billion portfolio spans five continents with interests in multiple sectors including aerospace, ICT, semiconductors, metals and mining, renewable energy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharmaceuticals and medical technology, agribusiness and a global portfolio of financial holdings across all asset classes. Mubadala has offices in Rio de Janeiro, Moscow, New York, San Francisco, and London.
Mubadala is a trusted partner, an engaged shareholder and a responsible global company that is committed to world-class standards of governance.
About National Reference Laboratory
National Reference Laboratory (NRL) is a Mubadala company created in partnership with and managed by LabCorp, a leading global life sciences company providing comprehensive clinical laboratory services. NRL’s vision is to increase the spectrum, coverage and overall efficiency of laboratory testing, to implement international best practice reference laboratory processes and to set the benchmark for quality standards in the region.
Together with the significant resources of LabCorp, NRL offers a comprehensive menu of more than 4,700 tests, providing a complete solution for all clinical testing needs in an efficient and high-quality environment that reduces both turnaround time and logistics-related costs, compared with other laboratories. The diverse and growing network of NRL currently includes eleven owned and managed laboratories across the UAE. For more information, please visit www.nrl.ae.
Media Contacts:
Salma Chalak, Consultant, Wallis PR
Telephone: +971 58 982 9525
Email: salma.chalak@wallispr.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
